Technical Data
PRAME (Melanoma Antigen Preferentially Expressed in Tumors, Opa-interacting Protein 4, OIP-4, Preferentially Expressed Antigen of Melanoma, MAPE, OIP4)
PRAME is a 509aa protein belonging to the PRAME family consisting of 7 LRR (leucine-rich) repeats. It is a tumor antigen expressed in human melanomas and is recognized by cytolytic T lymphocytes. It's overexpression frequently observed in human cancers confers growth or survival advantages by antagonizing retinoic acid receptor (RAR) signaling. PRAME serves as a candidate marker for monitoring childhood acute leukemia. It is expressed in testis and acute leukemias.

Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
ELISA: 0.1-1ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceHumanRabbit
Synthetic peptide corresponding to aa148-163 (EPEAAQPMTKKRKVDG) of human PRAME.
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, 0.2% gelatin, 0.05% sodium azide.
Recognizes human PRAME. Species Crossreactivity: chimpanzee.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Steinbach,D., Hermann,J., Viehmann,S., Zintl,F. and Gruhn,B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia Cancer Genet. Cytogenet. 133 (2), 118-123 (2002).